1. Asymmetric dimethylarginine (ADMA) mediates the effect of miRNA-762 on all-cause mortality in patients with coronary artery disease (CAD). (August 2021) Authors: Tselmin, S.; Kleber, M.; Jarzebska, N.; März, W.; Jin, H.; Bornstein, S.R.; Mangoni, A.; Rodionov, R.N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e222 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Transgenic overexpression of dimethylarginine dimethylaminohydrolase 1 protects from angiotensin II - induced cardiac hypertrophy and vascular remodeling. (August 2021) Authors: Kopaliani, I.; Jarzebska, N.; Brilloff, S.; Kolouschek, A.; Martens-Lobenhoffer, J.; Bornstein, S.R.; Bode-Böger, S.M.; Weiss, N.; Deussen, A.; Rodionov, R.N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗